Key Points
- CEO Martine Rothblatt sold 9,500 shares on April 6 at an average price of $558.41 for a total of $5.3049 million, leaving her with 40,513 shares (a 19% reduction) under a pre-arranged Rule 10b5-1 trading plan.
- The company reported quarterly EPS of $7.70, beating the $6.78 consensus while revenue was $790.2M (below the $814.8M estimate); net margin was strong at 41.9% and revenue grew 7.4% year-over-year.
- Shares trade near $565.70 with a market cap of ~$24.8B and a PE of 20.3, and analyst sentiment is broadly positive (nine Buys vs. three Holds) with a consensus target of about $586.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the company's stock in a transaction on Monday, April 6th. The stock was sold at an average price of $558.41, for a total transaction of $5,304,895.00. Following the transaction, the chief executive officer owned 40,513 shares of the company's stock, valued at $22,622,864.33. This represents a 19.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
United Therapeutics Stock Performance
NASDAQ:UTHR opened at $565.70 on Wednesday. The company has a fifty day moving average of $510.21 and a two-hundred day moving average of $481.87. The stock has a market capitalization of $24.79 billion, a PE ratio of 20.28, a P/E/G ratio of 1.63 and a beta of 0.75. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $607.89.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, topping analysts' consensus estimates of $6.78 by $0.92. The company had revenue of $790.20 million during the quarter, compared to analysts' expectations of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The firm's revenue for the quarter was up 7.4% on a year-over-year basis. During the same period in the prior year, the business posted $6.19 earnings per share. Research analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current year.
Institutional Investors Weigh In On United Therapeutics
Large investors have recently modified their holdings of the business. Torren Management LLC purchased a new stake in shares of United Therapeutics during the fourth quarter worth $26,000. Activest Wealth Management grew its holdings in shares of United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company's stock worth $29,000 after buying an additional 56 shares in the last quarter. Entrust Financial LLC purchased a new stake in shares of United Therapeutics during the fourth quarter worth $31,000. Wilmington Savings Fund Society FSB grew its holdings in shares of United Therapeutics by 125.6% in the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company's stock valued at $37,000 after purchasing an additional 49 shares during the period. Finally, Harbor Capital Advisors Inc. purchased a new stake in shares of United Therapeutics in the fourth quarter valued at about $48,000. Hedge funds and other institutional investors own 94.08% of the company's stock.
Analyst Upgrades and Downgrades
A number of equities analysts have weighed in on the stock. Oppenheimer upped their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an "outperform" rating in a research report on Thursday, February 26th. TD Cowen upped their target price on shares of United Therapeutics from $575.00 to $660.00 and gave the stock a "buy" rating in a report on Monday, March 30th. Royal Bank Of Canada upped their target price on shares of United Therapeutics from $587.00 to $643.00 and gave the stock an "outperform" rating in a report on Thursday, February 26th. HC Wainwright upped their target price on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a "buy" rating in a report on Tuesday, March 31st. Finally, Wells Fargo & Company upped their target price on shares of United Therapeutics from $486.00 to $575.00 and gave the stock an "equal weight" rating in a report on Tuesday, March 31st. Nine research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $586.00.
View Our Latest Analysis on UTHR
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
